Celgene

This study tests a new drug, golcadomide, combined with rituximab in 90 adults with newly diagnosed advanced follicular lymphoma who have not had prior treatment. The goal is to see if the combination can achieve complete metabolic response (disappearance of cancer signs on scans…

This study tests two new drug combinations for adults newly diagnosed with a specific type of acute myeloid leukemia (AML) that has an IDH1 or IDH2 mutation. Participants receive either one of the targeted pills (AG-120 or AG-221) plus a standard shot (azacitidine), or azacitidin…

This study tests a treatment called JCAR017, made from a patient's own immune cells that are modified to attack cancer. It is for adults with a slow-growing type of non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to see if the treatment can …

This study tests an experimental oral drug called CC-99282, taken alone or with other lymphoma treatments, in people whose non-Hodgkin lymphoma has returned or not responded to prior therapy. The main goals are to check safety, find the best dose, and see if the drug helps shrink…

This study compares a new three-drug combination (iberdomide, daratumumab, and dexamethasone) against a standard three-drug combination (daratumumab, bortezomib, and dexamethasone) in about 939 adults whose multiple myeloma has returned or stopped responding after 1-2 prior treat…

This study tests a new drug called CC-220, alone or with other medicines, in people with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see how well it controls the cancer. About 466 adults will take part, and the treatment is given as pills or …

This study tests whether adding the experimental drug golcadomide to standard chemotherapy (R-CHOP) works better than chemo alone for people with untreated high-risk large B-cell lymphoma. About 850 participants will receive either the combination or a placebo plus chemo. The mai…

This study tests whether adding a one-time CAR T-cell treatment (idecabtagene vicleucel) to standard lenalidomide maintenance therapy can better control multiple myeloma in adults who had a stem cell transplant but didn't get a full response. About 79 participants will receive ei…

This study follows over 900 newly diagnosed multiple myeloma patients who cannot have a stem cell transplant. Researchers compare heart-related side effects between those taking lenalidomide and those on other standard treatments. The goal is to better understand the safety of le…